WO2005000192A3 - Inhibiteurs de la glycogene synthase kinase-3 - Google Patents

Inhibiteurs de la glycogene synthase kinase-3 Download PDF

Info

Publication number
WO2005000192A3
WO2005000192A3 PCT/IL2004/000570 IL2004000570W WO2005000192A3 WO 2005000192 A3 WO2005000192 A3 WO 2005000192A3 IL 2004000570 W IL2004000570 W IL 2004000570W WO 2005000192 A3 WO2005000192 A3 WO 2005000192A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
glycogen synthase
synthase kinase
gsk
same
Prior art date
Application number
PCT/IL2004/000570
Other languages
English (en)
Other versions
WO2005000192A2 (fr
Inventor
Hagit Eldar-Finkelman
Original Assignee
Univ Tel Aviv Future Tech Dev
Hagit Eldar-Finkelman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tel Aviv Future Tech Dev, Hagit Eldar-Finkelman filed Critical Univ Tel Aviv Future Tech Dev
Priority to CN2004800240175A priority Critical patent/CN1838954B/zh
Priority to JP2006516816A priority patent/JP2007527859A/ja
Priority to EP04744910A priority patent/EP1638557A4/fr
Priority to CA002530111A priority patent/CA2530111A1/fr
Publication of WO2005000192A2 publication Critical patent/WO2005000192A2/fr
Publication of WO2005000192A3 publication Critical patent/WO2005000192A3/fr
Priority to US11/280,209 priority patent/US7378432B2/en
Priority to US12/149,336 priority patent/US8088941B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

L'invention concerne des composés capables d'inhiber l'activité de GSK-3, des compositions pharmaceutiques les contenant et leurs procédés d'utilisation dans le traitement d'états à médiation GSK-3.
PCT/IL2004/000570 2001-09-14 2004-06-27 Inhibiteurs de la glycogene synthase kinase-3 WO2005000192A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN2004800240175A CN1838954B (zh) 2003-06-27 2004-06-27 糖原合酶激酶-3抑制剂
JP2006516816A JP2007527859A (ja) 2003-06-27 2004-06-27 グリコーゲンシンターゼキナーゼ−３阻害剤
EP04744910A EP1638557A4 (fr) 2003-06-27 2004-06-27 Inhibiteurs de la glycogene synthase kinase-3
CA002530111A CA2530111A1 (fr) 2003-06-27 2004-06-27 Inhibiteurs de la glycogene synthase kinase-3
US11/280,209 US7378432B2 (en) 2001-09-14 2005-11-17 Glycogen synthase kinase-3 inhibitors
US12/149,336 US8088941B2 (en) 2001-09-14 2008-04-30 Glycogen synthase kinase-3 inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48271903P 2003-06-27 2003-06-27
US60/482,719 2003-06-27
US52849503P 2003-12-11 2003-12-11
US60/528,495 2003-12-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/810,578 Continuation-In-Part US7157422B2 (en) 2000-01-03 2004-03-29 Glycogen synthase kinase-3 inhibitors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2005234687A Division AU2005234687A1 (en) 2003-06-27 2005-11-17 Glycogen Synthase Kinase-3 Inhibitors
US11/280,209 Continuation-In-Part US7378432B2 (en) 2001-09-14 2005-11-17 Glycogen synthase kinase-3 inhibitors

Publications (2)

Publication Number Publication Date
WO2005000192A2 WO2005000192A2 (fr) 2005-01-06
WO2005000192A3 true WO2005000192A3 (fr) 2005-06-02

Family

ID=33555590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2004/000570 WO2005000192A2 (fr) 2001-09-14 2004-06-27 Inhibiteurs de la glycogene synthase kinase-3

Country Status (6)

Country Link
EP (1) EP1638557A4 (fr)
JP (1) JP2007527859A (fr)
KR (1) KR20060018902A (fr)
CN (1) CN1838954B (fr)
CA (1) CA2530111A1 (fr)
WO (1) WO2005000192A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049709A1 (fr) 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Inhibiteurs de glycogene synthase kinase-3
US7378432B2 (en) 2001-09-14 2008-05-27 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
EP1569956B1 (fr) 2002-12-12 2014-02-26 Tel Aviv University Future Technology Development L.P. Inhibiteurs de la glycogene synthase kinase-3
AU2005234687A1 (en) * 2003-06-27 2005-12-08 Tel Aviv Universtiy Future Technology Development L.P. Glycogen Synthase Kinase-3 Inhibitors
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
CA2741672A1 (fr) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabetiques utiles avec des derives de benzimidazole cycliques
CA2786314A1 (fr) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Nouveaux derives benzimidazole cycliques utiles comme agents antidiabetiques
EP2668199B1 (fr) 2011-01-27 2017-09-06 Ramot at Tel Aviv University, Ltd. Inhibiteurs de glycogène synthase kinase-3
WO2012101601A1 (fr) 2011-01-27 2012-08-02 Ramot At Tel-Aviv University Ltd. Inhibiteurs de glycogène synthase kinase 3
KR101668514B1 (ko) 2011-02-25 2016-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
EP3013850B1 (fr) 2013-06-24 2018-07-25 Ramot at Tel-Aviv University Ltd. Inhibiteurs de glycogène synthase kinase-3
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2018106518A1 (fr) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Composés hétérocycliques antidiabétiques
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049709A1 (fr) * 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Inhibiteurs de glycogene synthase kinase-3

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB785457A (en) * 1954-09-10 1957-10-30 Ici Ltd Phosphated metallisable azo dyestuffs
GB781806A (en) * 1955-04-29 1957-08-28 Roche Products Ltd Organic phosphate, salts thereof, and process for the manufacture thereof
JPS49125510A (fr) * 1973-04-11 1974-12-02
JPS57212704A (en) * 1981-06-24 1982-12-27 Fujikura Ltd Electric cable
JPS5871937A (ja) * 1981-10-23 1983-04-28 Adeka Argus Chem Co Ltd ハロゲン含有樹脂組成物
JPS63250063A (ja) * 1987-04-03 1988-10-17 Matsushita Electric Ind Co Ltd 亜鉛アルカリ電池
US6077954A (en) * 1996-08-01 2000-06-20 Isis Pharmaceuticals, Inc. Substituted heterocyclic compounds
US6441140B1 (en) * 1998-09-04 2002-08-27 Cell Signaling Technology, Inc. Production of motif-specific and context-independent antibodies using peptide libraries as antigens
WO2002016318A1 (fr) * 2000-08-21 2002-02-28 Pacific Corporation Nouveaux derives de thiourea et compositions pharmaceutiques renfermant ceux-ci
CA2451994C (fr) * 2001-07-16 2011-03-22 Teijin Limited Catalyseur destine a la production de polyester et procede de production de polyester faisant intervenir ce catalyseur

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049709A1 (fr) * 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Inhibiteurs de glycogene synthase kinase-3

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1638557A4 *

Also Published As

Publication number Publication date
WO2005000192A2 (fr) 2005-01-06
KR20060018902A (ko) 2006-03-02
EP1638557A4 (fr) 2007-11-07
EP1638557A2 (fr) 2006-03-29
JP2007527859A (ja) 2007-10-04
CN1838954B (zh) 2013-01-16
CN1838954A (zh) 2006-09-27
CA2530111A1 (fr) 2005-01-06

Similar Documents

Publication Publication Date Title
WO2004078116A3 (fr) Inhibiteurs de la p 38 et leurs procedes d'utilisation
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
WO2005000192A3 (fr) Inhibiteurs de la glycogene synthase kinase-3
WO2007064872A3 (fr) Composes de l'uree utilises dans le traitement du cancer
WO2006045119A3 (fr) Inhibiteurs ameliores de l'epoxyde hydrolase soluble
WO2007064945A3 (fr) Therapies contre le cancer et compositions pharmaceutiques utilisees dans ces therapies
WO2005002552A3 (fr) Composes pharmaceutiques
WO2005028475A3 (fr) Compositions utiles pour inhiber des proteines kinases
WO2006031806A3 (fr) 2-thiopyrimidinones utilises en tant qu'agents therapeutiques
WO2007106537A3 (fr) Aminoquinolones utilisées comme inhibiteurs de la gsk-3
IL220480A0 (en) 1-benzyl-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors , preparation method thereof, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
WO2008098104A8 (fr) Inhibiteurs de l'activité de akt
WO2007059202A3 (fr) Derives de pyrazolyluree utilisables dans le traitement du cancer
WO2006086562A3 (fr) Derives de phenylazetidinone
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2005105780A3 (fr) Compositions utiles en tant qu'inhibiteurs de la rock et d'autres proteines kinases
WO2003097794A3 (fr) Amorces oligonucleotidiques universelles marquees et procedes d'utilisation
WO2002096361A3 (fr) Derives de 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone utilises comme inhibiteurs de kinase
WO2005103050A3 (fr) Azaindoles utiles en tant qu'inhibiteurs de la proteine serine/threonine kinase superhelice de la famille rho (rock) et d'autres proteines kinases
WO2004089296A3 (fr) Inhibiteurs ameliores pour hydrolase epoxyde soluble
AP2005003452A0 (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
IL176478A0 (en) Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the faah enzyme
WO2005056547A3 (fr) Quinoxalines utiles comme inhibiteurs des proteines kinases
WO2005039485A3 (fr) Inhibiteurs de gsk-3 et utilisations
WO2004073623A3 (fr) Traitement d'etats pathologiques associes a la biodisponibilite reduite de l'oxyde nitrique, y compris des etats pathologiques causes par l'activite elevee de l'arginase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480024017.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172038

Country of ref document: IL

Ref document number: 11280209

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004744910

Country of ref document: EP

Ref document number: 2530111

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006516816

Country of ref document: JP

Ref document number: 1020057025051

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 343/CHENP/2006

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 1020057025051

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004744910

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11280209

Country of ref document: US